Unknown

Dataset Information

0

Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy.


ABSTRACT: TIM3 belongs to a family of receptors that are involved in T-cell exhaustion and Treg functions. The development of new therapeutic agents to block this type of receptors is opening a new avenue in cancer immunotherapy. There are currently several clinical trials ongoing to combine different immune-checkpoint blockades to improve the outcome of cancer patients. Among these combinations we should underline PD1:PDL1 axis and TIM3 blockade, which have shown very promising results in preclinical settings. Most of these types of therapeutic agents are protein cell-derived products, which, although broadly used in clinical settings, are still subject to important limitations. In this work we identify by HT-SELEX TIM3 non-antigenic oligonucleotide aptamers (TIM3Apt) that bind with high affinity and specificity to the extracellular motives of TIM3 on the cell surface. The TIM3Apt1 in its monomeric form displays a potent antagonist capacity on TIM3-expressing lymphocytes, determining the increase of IFN-? secretion. In colon carcinoma tumor-bearing mice, the combinatorial treatment of TIM3Apt1 and PDL1-antibody blockade is synergistic with a remarkable antitumor effect. Immunotherapeutic aptamers could represent an attractive alternative to monoclonal antibodies, as they exhibit important advantages; namely, lower antigenicity, being chemically synthesized agents with a lower price of manufacture, providing higher malleability, and antidote availability.

SUBMITTER: Hervas-Stubbs S 

PROVIDER: S-EPMC4826223 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy.

Hervas-Stubbs Sandra S   Soldevilla Mario M MM   Villanueva Helena H   Mancheño Uxua U   Bendandi Maurizio M   Pastor Fernando F  

Oncotarget 20160101 4


TIM3 belongs to a family of receptors that are involved in T-cell exhaustion and Treg functions. The development of new therapeutic agents to block this type of receptors is opening a new avenue in cancer immunotherapy. There are currently several clinical trials ongoing to combine different immune-checkpoint blockades to improve the outcome of cancer patients. Among these combinations we should underline PD1:PDL1 axis and TIM3 blockade, which have shown very promising results in preclinical set  ...[more]

Similar Datasets

| S-EPMC4499121 | biostudies-literature
| S-EPMC4281958 | biostudies-literature
| S-EPMC7641312 | biostudies-literature
| S-EPMC8685993 | biostudies-literature
| S-EPMC5608357 | biostudies-literature
| S-EPMC4067300 | biostudies-literature
| S-EPMC6579568 | biostudies-literature
| S-EPMC4884992 | biostudies-literature
| S-EPMC9218155 | biostudies-literature
| S-EPMC8168453 | biostudies-literature